# Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

Source: https://onco.cc/trials/nct06730009/  
OnCo record `nct06730009` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SLOG + Allogeneic NK cell in pancreatic ductal adenocarcinoma and biliary tract cancer, run by Medigen Biotechnology Corporation, now recruiting.

## Summary

Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients is a phase 1/2 interventional study registered as NCT06730009 by Medigen Biotechnology Corporation, with 42 participants planned, started 2024-10-21 and due to reach its primary completion in 2029-01-31. Interventions recorded: SLOG + Allogeneic NK cell and SLOG chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06730009
- Phase: 1/2
- Setting: A Dose-Finding Phase I Followed by a Phase II Study to Evaluate the Safety and Efficacy of Allogeneic NK-cell Combined With Chemotherapy in Patients With PDA or Cholangiocarcinoma After Surgery
- Sponsor: Medigen Biotechnology Corporation
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT06730009: https://clinicaltrials.gov/study/NCT06730009

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct06730009.json